218-221)
IMHO, the above cautions, coupled with higher SVR-rates in the setting of
growth factor use for hemotologic complications, provides reason for the medical community to continue administration even when risks are low:
" Granulocyte colony-stimulating factor for hepatitis C therapy-associated neutropenia: systematic review and economic evaluation. "
Author: Tandon, P.; Doucette, K.; Fassbender, K.; Vandermeer, B.; Durec, T.; Dryden, D. M.; Add.Author / Editor: Tandon, P.